title: Re-implantation after insufficient primary 125-i permanent prostate brachytherapy.
abstract: BACKGROUND
  We describe five patients receiving a re-implantation (RI) after post-operative dosimetry of the primary 125-I permanent prostate brachytherapy (BT) for prostate cancer revealed an insufficient dose coverage.
  
  
  METHODS
  Five out of 222 consecutive patients treated (from March, 2001 to August, 2012) with 125-I BT, received a RI after dosimetric verification by CT and MRI fusion four to eight weeks after implantation displayed an insufficient dose coverage. RIs were performed with 10 to 19 seeds, three to four months after primary intervention. Dosimetry after RI showed an improved and sufficient total dose coverage in all patients.
  
  
  RESULTS
  At last follow-up (18 to 99 months, median 57 months), none of the patients had relevant implant associated side-effects. Functional outcome was comparable to patients after one-time implantation. PSA levels post intervention showed a decreasing tendency in 4 patients. One patient had a local recurrence after 12 months.
  
  
  CONCLUSIONS
  In our series, approximately 2% of the patients treated with permanent prostate BT required a RI due to insufficient dose coverage. None of the patients who underwent RI experienced complications. Our series, although only with 5 cases and limited follow-up, along with other published reports, demonstrates good tolerability.
authors.affiliation: Department of Radiation Oncology, Kantonsspital St, Gallen, 9007 St, Gallen, Switzerland. paul.putora@kssg.ch.
authors.forename: Paul Martin
authors.initials: PM
authors.lastname: Putora
authors.forename: Ludwig
authors.initials: L
authors.lastname: Plasswilm
authors.forename: Wolf
authors.initials: W
authors.lastname: Seelentag
authors.forename: Johann
authors.initials: J
authors.lastname: Schiefer
authors.forename: Patrick
authors.initials: P
authors.lastname: Markart
authors.forename: Hans-Peter
authors.initials: HP
authors.lastname: Schmid
authors.forename: Daniel
authors.initials: D
authors.lastname: Engeler
mesh_terms: D000230:Adenocarcinoma / Q000532:radiotherapy*; D000368:Aged; D001918:Brachytherapy; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000532:radiotherapy; D011874:Radiometry; D011879:Radiotherapy Dosage; D012086:Reoperation
chemical_list: D007457:Iodine Radioisotopes
references.citation: Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):327-33
references.pmid: 17084558
references.citation: Radiother Oncol. 2009 May;91(2):202-6
references.pmid: 18950884
references.citation: Strahlenther Onkol. 2011 Jun;187(6):367-72
references.pmid: 21603993
references.citation: Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):221-30
references.pmid: 10656396
references.citation: Brachytherapy. 2009 Apr-Jun;8(2):197-206
references.pmid: 19433321
references.citation: Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):40-50
references.pmid: 15337538
references.citation: Eur Urol. 2003 Jul;44(1):40-6
references.pmid: 12814673
references.citation: Semin Radiat Oncol. 2003 Jul;13(3):176-81
references.pmid: 12903007
references.citation: Brachytherapy. 2012 Jan-Feb;11(1):6-19
references.pmid: 22265434
references.citation: Brachytherapy. 2005;4(2):163-70
references.pmid: 15893271
references.citation: Eur Urol. 2002 Apr;41(4):434-9
references.pmid: 12074816
references.citation: Strahlenther Onkol. 2010 Oct;186(10):531-4
references.pmid: 20890742
references.citation: Med Phys. 2009 Nov;36(11):5235-44
references.pmid: 19994534
references.citation: Strahlenther Onkol. 2012 Apr;188(4):305-10
references.pmid: 22349713
references.citation: BJU Int. 2006 Jan;97(1):62-8
references.pmid: 16336330